Our n.c.a Lu-177 stands out due to its unique advantages:
Our raw material enrichment capabilities minimize the risk of shortages of this key isotope. Longer term irradiation can be done in our Mo-99 facility, which addresses potential cost, access, and logistical challenges, including wasted product from Lu-177 decay. Once scaled, production will be possible of hundred-curie-level quantities of Lu-177 with hundreds of doses per batch, a substantial increase to the batch-limits from traditional production methods.
Our Lu-177 production system has the flexibility to irradiate targets employing both next generation technologies and more traditional modalities. Our in-house, fusion-based technology is aligned with good manufacturing practices and our proprietary separation technology allows for larger batch sizes and an unparalleled ability to scale production. Our n.c.a. Lu-177 will be shipping from our U.S. facility in Janesville, Wisconsin, in close proximity to many specialized manufacturing sites for therapeutic radiopharmaceuticals, reducing logistical challenges and the significant loss of product in transport.